DAINIPPON SUMITOMO PHARMA CO LTD | 11,445 Euro | -0,28 -2,39 % | |
| WKN: 858257 ISIN: JP3495000006 Ticker-Symbol: DPM | Stuttgart | 24.05.13 | 08:09 Uhr |
Branche PharmaAktienmarkt NIKKEI-225 |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 29.03. | Retina Institute Japan und Dainippon Sumitomo Pharma gründen Kapitalallianz zur Entwicklung der mit dem Nobel-Preis ausgezeichneten iPS-Zelltechnologie | 275 | Business Wire | |
| Retina Institute Japan K.K. (RIJ) (Hauptsitz: Fukuoka, Japan; Präsident: Hardy T S Kagimoto, MD) und Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Hauptsitz: Osaka, Japan; Präsident: Masayo... Mehr lesen zu: Retina Institute Japan und Dainippon Sumitomo Pharma gründen Kapitalallianz zur Entwicklung der mit dem Nobel-Preis ausgezeichneten iPS-Zelltechnologie | ||||
| 29.03. | Retina Institute Japan and Dainippon Sumitomo Pharma Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology | 160 | Business Wire | |
| Retina Institute Japan K.K. (RIJ) (Headquarters: Fukuoka, Japan; President: Hardy T S Kagimoto, MD) and Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo... Mehr lesen zu: Retina Institute Japan and Dainippon Sumitomo Pharma Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology | ||||
| 28.03. | Dainippon Sumitomo To Take 5% Stake In Bioventure | - | Nikkei.com | |
| 28.03. | Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs | 51 | PR Newswire | |
| MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ --Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreementwithDainippon... Mehr lesen zu: Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs | ||||
| 21.01. | BIZ BRIEF: Dainippon Sumitomo Pharma establishes subsidiary in Singapore | 2 | Asahi Shimbun | |
| 25.09. | XFRA DIVIDEND INFORMATION - 26.09.2012 - 8 | 366 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 25.09.2012 CUM DIVIDENDE UND AM 26.09.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 25.09.2012. THE
EX-DIVIDEND DAY WILL BE 26.09.2012.
... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 26.09.2012 - 8 | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| DAIICHI SANKYO | 13,92 | +0,87 % | Indian Billionaire Brothers Prepare To Fight Daiichi Sankyo |
| EISAI | 31,193 | -1,46 % | The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does |
| ASTELLAS PHARMA | 40,598 | -4,82 % | Astellas erhält von der niederländischen Arzneimittelbehörde die Marktzulassung für VESOMNI(TM) |
| ABBOTT LABORATORIES | 29,019 | +0,01 % | Goldman Sachs stuft Abbott Labs von Neutral auf Buy hoch |
| KYOWA HAKKO KOGYO | 8,462 | -6,31 % | XFRA DIVIDEND INFORMATION - 27.12.2012 - 4 |
